Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment J. H. HooijbergN. A. de VriesG. J. Peters Review 15 December 2005 Pages: 1 - 12
Bortezomib interactions with chemotherapy agents in acute leukemia in vitro Terzah M. HortonAnurhadha GannavarapuStacey L. Berg Original Article 15 November 2005 Pages: 13 - 23
Elemene displays anti-cancer ability on laryngeal cancer cells in vitro and in vivo Lei TaoLiang ZhouMin Yao Original Article 10 November 2005 Pages: 24 - 34
CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas Jong Gwang KimSang Kyun SohnChang-Hak Sohn Original Article 25 November 2005 Pages: 35 - 39
Chemoprotection effect of retroviral vector encoding multidrug resistance 1 gene to allow intensified chemotherapy in vivo Chun-Bao GuoYing-Cun LiXian-Qing Jin Original Article 12 November 2005 Pages: 40 - 49
Human breast cell lines exhibit functional α2-adrenoceptors Stella Maris VázquezAlejandro Gustavo MladovanIsabel Alicia Lüthy Original Article 15 November 2005 Pages: 50 - 61
Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells Eileen BrantleySmitha AntonyYves Pommier Original Article 06 December 2005 Pages: 62 - 72
Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization William C. RosePunit H. MaratheMansukh C. Wani Original Article 14 October 2005 Pages: 73 - 85
Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer Kiyoshi MoriYukari KamiyamaTetsuro Kodama Original Article 31 January 2006 Pages: 86 - 90
p53 Status does not affect photodynamic cell killing induced by hypericin H. B. LeeA. S. H. HoS. H. Teo Original Article 07 October 2005 Pages: 91 - 98
Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein Qiangrong PanQinghua LuXun Hu Original Article 18 October 2005 Pages: 99 - 106
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors Joseph P. Eder JrDavid P. RyanJeffrey G. Supko Original Article 13 December 2005 Pages: 107 - 116
Enforced expression of cytosolic 5′-nucleotidase I confers resistance to nucleoside analogues in vitro but systemic chemotherapy toxicity precludes in vivo selection Tasha GrayErin L. MorreyH. Trent Spencer Original Article 15 December 2005 Pages: 117 - 128
Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme Anne F. SchottJames M. RaeLaurence H. Baker Clinical Trial Report 08 November 2005 Pages: 129 - 135
5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice Muhammad Wasif SaifReid von Borstel Clinical Trial Report 27 September 2005 Pages: 136 - 142